Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Gate2Brain at MIT Pitch Day at University of Cambridge

News
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day šŸ—£ļøat the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day at the University of Cambridge, the cradle of cancer research.

The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies.

A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care.

June 30, 2022/by noticias
Tags: academic, Biotech, entrepreneurship, investors, pitch, preclinical, research
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2022/06/cambridge-foto.jpeg 768 1024 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2022-06-30 11:22:462022-06-30 11:22:46Gate2Brain at MIT Pitch Day at University of Cambridge
You might also like
Grit International Female Accelerator!Grit International Female AcceleratorG2B joined the Grit International Female Accelerator
Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck
Womenstartupawardsgate2BrainWomenStarUpAwards
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
G2B receives funding to accelerate its transfer to the market and society
10 Top Biotech Startups to Watch in 2023StartUs10 Top Biotech Startups to Watch in 2023
Nadia CalviƱo, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJDNadia CalviƱo, First Vice President of the Government visits Gate2Brain
Three University of Barcelona spin-offs led by women will receive funding as part of the Women TechEU pilot callFundació Bosch i GimperaThree University of Barcelona spin-offs will receive funding from Women TechEU pilot call

CATEGORIES

  • Advisory Board
  • Clipping
  • Events
  • G2B family
  • Media
  • News
  • Podcast
  • Press releases
  • Publications
  • Team
  • Videos

Events

  • Bio-Europe 2023November 17, 2023 - 14:01
  • Science Week 2023November 16, 2023 - 17:07
  • Inv€$tival Showcase – LSXNovember 9, 2023 - 07:45
  • Gate2Brain honored with an award as part of the EIT Health “Wild Card” programOctober 30, 2023 - 10:52
  • World Orphan Drug Congress Europe 2023October 19, 2023 - 20:54

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
Ā© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Medicines beyond barriersmedicines beyond barriersG2BIt’s Gate2Brain second anniversary!! šŸŽ‚ The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2BrainGate2Brain second anniversary
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}